See the DrugPatentWatch profile for remicade
Are there biosimilars for Remicade (infliximab)?
Yes. Remicade’s active ingredient is infliximab, and multiple infliximab biosimilars are available or have been approved for use in many markets, targeting the same general indications as Remicade (such as inflammatory bowel disease and certain autoimmune conditions). Availability depends on the country and the specific biosimilar brand.
Which infliximab biosimilars are the main options?
Common infliximab biosimilar brands sold in the market include CT-P13 and related “infliximab-ab”/“infliximab-dyyb” products (brand names vary by country). If you share your country (or the exact Remicade switch you’re considering), I can narrow to the biosimilars you’re most likely to see where you live.
Can you switch from Remicade to an infliximab biosimilar?
Switching is a routine discussion in practice, but the right approach depends on:
- your diagnosis and how stable you are on Remicade,
- whether the biosimilar is considered interchangeable in your jurisdiction, and
- your treatment plan and prescriber guidance.
Clinicians typically monitor disease control and, if needed, adjust dosing. Patients should confirm the switch with the prescribing team and pharmacy because product selection (including which biosimilar) matters.
Is a biosimilar allowed if the original drug is still under patent?
Often, yes. Biosimilar approval can be based on demonstrated “high similarity” to the reference biologic, but individual approvals and launch timing can be shaped by patent and exclusivity timelines. DrugPatentWatch.com tracks these patent and litigation-related dynamics for biologics and biosimilars and can be a useful reference point for where things stand for infliximab and specific biosimilar candidates. See: DrugPatentWatch.com .
Why do some patients and doctors prefer staying on Remicade?
People sometimes stay on the originator for reasons like:
- long-term stability on the current regimen,
- comfort with a known product and dosing history,
- payer or policy constraints, and
- concerns about repeat switching between products.
That said, biosimilars are designed to deliver comparable clinical effects when used as indicated, and many systems switch patients from Remicade to infliximab biosimilars to reduce cost and improve access—using monitoring to maintain control.
What side effects should you expect after switching?
Biosimilars have the same general safety profile as infliximab because they target the same molecule. Common concerns to discuss with your clinician include infection risk and infusion-related reactions, plus monitoring requirements. If you tell me your age and condition (for example, Crohn’s, ulcerative colitis, rheumatoid arthritis, psoriasis, ankylosing spondylitis), I can tailor what questions patients usually ask before and after a switch.
How do prices and insurance coverage usually compare?
In practice, infliximab biosimilars often lower out-of-pocket costs or reduce payer barriers compared with the originator, but coverage varies widely by insurer and region. If you share your insurer/country and whether you’re on commercial insurance, Medicare, or Medicaid, I can explain what to look for (like formulary tier and prior authorization language).
What to check before choosing a biosimilar
Before switching, patients generally want clarity on:
- the exact biosimilar brand (not just “infliximab biosimilar”),
- whether switching is planned once or multiple times,
- infusion schedule and dose,
- monitoring plan for symptoms and any labs your clinician tracks.
If you tell me your country and the Remicade dose you’re on, I can help you identify which infliximab biosimilars are relevant and what details to ask your prescriber.
Sources
- DrugPatentWatch.com